公开(公告)号：EP3412670A1

公开(公告)日：2018-12-12

申请号：EP17747634.8

申请日：2017-01-11

申请人： Samjin Pharmaceutical Co., Ltd. ,  Incheon University Industry Academic Cooperation Foundation ,  BAMICHEM CO., LTD

发明人： CHO, Eui Hwan ,  SHIN, Hee Jong ,  KI, Min Hyo ,  KWON, Ho Seok ,  LEE, Jae Woong ,  JOO, Jeong Ho ,  LEE, Keun Kuk ,  KIM, Jong Min ,  PARK, Yong Bin ,  KANG, Sung Hyun ,  CHO, Hyoung Min ,  KIM, Hyun Tae ,  AHN, Soon Kil ,  HONG, Sung Pyo ,  KIM, Sung Hye

IPC分类号： C07D473/00 ,  C07D487/04 ,  C07D401/04 ,  C07D401/14 ,  A61K31/52 ,  A61K31/519

CPC分类号： A61K31/519 ,  A61K31/52 ,  C07D401/04 ,  C07D401/14 ,  C07D473/00 ,  C07D487/04

摘要： The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.

公开(公告)号：EP3411020A1

公开(公告)日：2018-12-12

申请号：EP17747672.8

申请日：2017-01-24

申请人： Samjin Pharmaceutical Co., Ltd.

发明人： CHO, Eui Hwan ,  CHOI, Sung-Ju ,  LEE, Sung-Woo ,  SHIN, Hee-Jong ,  KI, Min-Hyo ,  CHOI, Mee-Hwa ,  OH, Tae-Hoon

IPC分类号： A61K9/28 ,  A61K9/48 ,  A61K47/44 ,  A61K31/403

CPC分类号： A61K9/284 ,  A61K9/2866 ,  A61K31/403

摘要： Disclosed is an immediate-release carvedilol formulation, which is configured such that a coating layer including a polymer, wax, fatty acid and/or fatty acid ester is formed on the surface thereof. This formulation has improved madescent, and thus can exhibit high stability, in which the initial appearance of the formulation can be maintained without cracking or breaking even under storage conditions at high relative humidity.

公开(公告)号：EP2732810A1

公开(公告)日：2014-05-21

申请号：EP11869405.8

申请日：2011-10-27

申请人： Samjin Pharmaceutical Co., Ltd. ,  Astech Co., Ltd.

发明人： CHO, Eui Hwan ,  SHIN, Hee Jong ,  SONG, Woo Heon ,  LEE, Sun Hwan ,  YOON, Jong Bae ,  PARK, Jong Sung

IPC分类号： A61K9/16 ,  A61K9/20 ,  C07D495/04 ,  A61K31/4365

CPC分类号： A61K9/14 ,  A61K9/20 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2095 ,  A61K31/4365 ,  C07D495/04 ,  Y10T428/2982

摘要： The present invention relates to spherical particles of clopidogrel bisulfate and a pharmaceutical composition containing the same. The inventive spherical particles can be used for preparing a tablet having sufficient hardness through direct compression, by improving unformulable properties of clopidogrel bisulfate such as compressibility, flowability and strong surface electrostatic charges, reduce a problem in compressing tablets such as weight variation, sticking, etc., and the risk of form conversion, and improve physiochemical stability. Therefore, the spherical particles of the present invention may be used as therapeutics for arteriosclerosis, stroke, myocardial infarction and atherosclerosis.

摘要翻译： 本发明涉及一种氯吡格雷硫酸氢盐和含有它们的药物组合物的球形颗粒。 本发明的球形颗粒可用于制备片剂具有通过直接压缩足够的硬度，通过提高硫酸氢氯吡格雷的unformulable属性：例如可压缩性，流动性和强的表面的静电荷，在压缩片剂减少了一个问题：如重量变化，粘着等 ，和晶型转化的风险，并提高生理化学稳定性。 因此，本发明的球形颗粒可以用作治疗动脉硬化，中风，心肌梗死和动脉粥样硬化。